Bisphosphonate Use May be Associated With an Increased Risk of Periprosthetic Hip Fracture.

Background: Osteoporosis is common among patients undergoing primary total hip arthroplasty (THA). This study aimed to evaluate the effect of bisphosphonate treatment on osteoporotic patients undergoing primary THA.

Methods: Using a national database, 30,137 patients who had osteoporosis before primary elective THA were identified during 2010 to 2020.

Fracture Risk Assessment and Drug Holiday in a Real-Life Setting.

Purpose: Describe fracture risk assessment practices among physicians treating osteoporosis in a real-life setting.

Methods: This is a retrospective cohort study in a tertiary academic center. Inclusion criteria involved adults (aged ≥18 years) who received minimum adequate therapy (bisphosphates, raloxifene, or denosumab ≥ 3 years or teriparatide ≥ 18 months).

Approaches to Fracture Risk Assessment and Prevention.

Purpose Of Review: To critically assess recent evidence concerning osteoporosis fracture risk.

Recent Findings: Robust instruments exist for predicting factures incorporating well-documented risk factors especially prior fracture whose magnitude varies with site, occurrence time, and age. Stratifying time-since-prior fracture has resulted in the concept of imminent fracture risk and increased focus on secondary fracture prevention.

Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial.

Unlabelled: Abaloparatide increased ultradistal radius bone mineral density (BMD) in the Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) trial. Over the subsequent 24 months in ACTIVExtend, ultradistal radius BMD gains were maintained with alendronate. Conversely, 1/3 radius BMD remained stable during ALN treatment in ACTIVExtend after decreasing during ACTIVE.